Wall Street Calls: Truist Starts Nebius at Buy, JPMorgan Lifts Meta Target to $820

According to CNBC, Truist initiated coverage of Nebius with a Buy rating and a $355 price target, saying it sees margin upside and describing the company as a scaling AI-native hyperscaler still building out its infrastructure. JPMorgan also reiterated Meta as overweight and raised its price target to $820 from $640, saying the company still has meaningful upside as it begins rolling out frontier models and AI-driven products beyond advertising. The note also said JPMorgan initiated SK Hynix as overweight with a Jun-27 price target of US$245, while Wells Fargo upgraded Synopsys to overweight from equal weight and Yum Brands to overweight from equal weight. Other calls included Deutsche Bank initiating Clover Health at Buy with a $6 price target, Morgan Stanley initiating Revolution Medicines at overweight, and Goldman Sachs initiating Abivax at Buy with 12-month price targets of €132 and ADR $155.